日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Science and Health

Drugmakers cut vaccine prices for poorer nations

(Agencies)
Updated: 2011-06-06 23:07
Large Medium Small

LONDON - Several leading drugmakers are cutting their prices on potentially life-saving vaccines for people in developing countries in an effort to sustain supplies via the GAVI international vaccine alliance.

The price cuts, offered by both generic and branded drugmakers including GlaxoSmithKline, Merck, Johnson & Johnson's Crucell and Sanofi-Aventis' Sanofi Pasteur, should help the alliance narrow a $3.7 billion funding gap for its commitments up until 2015.

GSK said on Monday it would provide its Rotarix rotavirus vaccine to GAVI at a 67 percent discount to the current public price -- bringing it to $2.50 per dose, or $5 to fully immunise a child.

Merck said it will offer its Rotateq rotavirus shot at $5.00 a dose initially. "The RotaTeq price will decrease to $3.50 once the purchase volume increases to 30 million doses," it said.

Julie Gerberding, president of Merck Vaccines said long-term purchase commitments help to speed up availability of vaccines.

"Confirming volumes to be purchased will enable further price reductions as manufacturers expand production and lower costs in the future allowing for greater access," she added.

Diarrhoea is one of the top two killers of children under five worldwide and rotavirus is the leading cause of severe diarrhoeal disease in children. Each year, rotavirus-related diarrhoea kills more than 500,000 children.

In 2009, the WHO recommended that all countries should include rotavirus vaccines in national vaccination programmes, but many poorer countries struggle to afford them.

GAVI, which funds bulk-buy vaccination programmes for nations that can't afford shots at Western prices, has committed to help fund rotavirus vaccine introduction in at least 40 of the world's poorest countries by 2015.

But the alliance is facing a shortfall of $3.7 billion to fund it projects through to 2015, and has been seeking extra donor money and price cuts from drug firms to close that gap. It has a pledging conference in London on June 13.

"These are promising offers that demonstrate industry commitment to work towards affordable and sustainable prices," Helen Evans, GAVI's interim chief executive, said in a statement.

GSK said it had offered to supply up to 125 million doses of Rotarix over five years at an approximately 95 percent price cut from the Western market price.

"Whilst most babies in the world will get rotavirus at some point, those in developing countries do not have access to the medical care they need which means millions of babies die unnecessarily," GSK's CEO Andrew Witty said in a statement.

He said the British drugmaker was committed to finding new ways to get urgently needed vaccines to children in poor countries.

Evans said that if rotavirus vaccine could be purchased this year at $2.50 a dose, the impact on public health could be significant and would allow GAVI to save approximately $500 million through to 2020, or about $140 million through to 2015.

The price GAVI pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, will also be cut by the India-based firms Serum Institute and Panacea Biotec.

Serum, which had already cut its price to $1.75 a dose, said it would "continue to provide the most competitive pricing," while Panacea said it would cut its price by up to 15 percent.

Crucell and Sanofi Pasteur said they would extend GAVI prices on their pentavalent vaccines to 16 countries who are moving on from GAVI support to begin buying shots themselves.

Sanofi Pasteur said this would also apply to its yellow fever vaccine and a rotavirus vaccine being developed by its Indian subsidiary Shantha.

Merck also announced it will offer GAVI its Gardasil shot, which protects the human papillomavirus (HPV) that causes cervical cancer, at a discounted price of $5 per dose -- a 67 percent reduction on the current public price.

Although GAVI has not yet committed to funding HPV vaccines, it said they were part of its investment strategy and it hoped "to see further price reductions." More than 90 percent of deaths from cervical cancer now occur in developing countries, killing 200,000 women a year.

分享按鈕
主站蜘蛛池模板: av男人天堂网 | 青青草福利视频 | 精品手机在线视频 | 中文字幕在线播放不卡 | 国产在线播放91 | 中国久久久久 | 免费看日韩av| 久久伊人国产 | 色综合久 | 五月婷婷一区二区三区 | 亚洲国产精品成人va在线观看 | 免费av在线网站 | 日韩欧美国产中文字幕 | 久久国产精品波多野结衣av | 成人免费视频国产免费 | 91网站免费看 | 欧洲精品在线观看 | 国产专区在线播放 | 少妇av一区二区三区 | 亚洲美女在线观看 | 国产黄页 | 激情第四色 | 51国产偷自视频区视频 | 欧美黑人三级 | 国产一区二区毛片 | 五月婷婷色丁香 | 欧美天堂在线视频 | 欧美一区二区在线播放 | 草在线视频 | www.亚洲色图.com | 国产黄色大片网站 | 91在线免费看 | 国产精品久久久一区二区三区 | 成人深夜福利 | xxx日本在线观看 | 四虎国产成人永久精品免费 | 五月激情婷婷丁香 | 久久一二区 | 手机免费观看av | 人人入人人 | 婷婷中文网 |